Program
[11C]ABBV-112i
A development code.
Its studies are led by AbbVie.
Furthest: early phase 1, since Nov 6, 20261 company-led study, 1 open or runningNext primary completion: Feb 2027 (early phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | early phase 1since Nov 6, 2026 | Nov 6, 2026 | Feb 2027early phase 1 · NCT07933497 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 6, 2026First study: early phase 1 study in Healthy VolunteersFirst studyNCT07933497 · 6 planned
Ahead
- Feb 2027Primary completion: early phase 1 study in Healthy VolunteersNCT07933497
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933497Healthy Volunteers | Early 1 | Not yet recruiting | Feb 2027 | 6 |
How it is read
Names in the registry
- “[11C]ABBV-112i”, 1 entry
Codes read as this program: ABBV112I.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.